| December 21, 2009
We spoke with Dr. Kent Willyard about his experience using Epocrates since it was introduced to healthcare professionals.
Between developing its own pipeline of therapies for patients with hepatitis C and acquiring another company known for its work in this field, it looks like Merck is taking steps to be a larger player in HCV market.
A new drug was given tentative approval by the US Food and Drug Administration to help patients with both type 1 and type 2 diabetes.
Fixed-dose tablet is the first sodium glucose cotransporter 2 (SGLT2) inhibitor plus metformin combo product to receive approval in the US.